Cardinal Health Q4 EPS Soars 70%, Guides FY27 Above Long-Term Target
CAH sits 73% above its 52-week low of $137.75.
Summary
Cardinal Health delivered a standout Q4, with GAAP diluted EPS surging 70% to $1.70 and non-GAAP EPS up 40% to $2.91, including a $0.31 benefit from IEEPA tariff refunds. Full-year non-GAAP EPS hit $11.26, up 37%, driven by double-digit profit growth across all five segments. The company generated $5.2 billion in operating cash flow and completed $1.4 billion in share repurchases, with a new $5.0 billion buyback authorization. FY27 non-GAAP EPS guidance of $12.40-$12.60 implies 13-15% growth, exceeding the long-term target. This follows the July acquisition of AdaptHealth's diabetes unit and a recent credit facility refinancing, underscoring strong capital deployment. The results and guidance signal broad-based operational momentum heading into the new fiscal year.
At the time of this announcement, CAH was trading at $238.00 on NYSE in the Trade & Services sector, with a market capitalization of approximately $55.5B. The 52-week trading range was $137.75 to $244.87. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.